Physician profile
Douglas K Hogarth
NPI 1619030137
$2,887,015.85
in general payments reported to CMS, 2019-2025
56 companies · $426K in 2025
The $426K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673K · 2020: $185K · 2021: $307K · 2022: $437K · 2023: $411K · 2024: $448K · 2025: $426K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $639K · Consulting Fee: $355K · Travel and Lodging: $133K · Education: $69K · Food and Beverage: $53K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $31K · Honoraria: $5,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $639,027.50 |
| Consulting Fee | $355,361.50 |
| Travel and Lodging | $133,295.48 |
| Education | $69,136.25 |
| Food and Beverage | $53,385.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $30,500.00 |
| Honoraria | $5,020.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $908,057.73 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Ethicon INC. | $558,954.12 | 2019-2023 | Monarch Platform |
| Noah Medical Corporation | $433,251.59 | 2023-2025 | Galaxy |
| Grifols USA, LLC | $247,073.57 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $176,107.33 | 2020-2025 | Glassia, Cuvitru |
| Pulmonx Corporation | $149,473.42 | 2019-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Boston Scientific Corporation | $62,609.49 | 2019-2024 | Acquire, Exalt Model D, Expect |
| Olympus America INC. | $54,721.65 | 2020-2025 | Spiration Valve System, Single-Use Flexible Video Bronchoscope |
| Amgen INC. | $46,355.11 | 2021-2025 | Tezspire |
| Ambu A/S | $46,144.49 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,539.44 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Ethicon Endo-Surgery INC. | $35,207.37 | 2022 | |
| Shire North American Group INC | $27,878.08 | 2019 | |
| Genentech USA, INC. | $11,551.33 | 2019-2025 | Xolair, Actemra |
| Genzyme Corporation | $9,907.55 | 2019-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $9,165.50 | 2019 | |
| Medical Device Business Services, INC. | $8,790.50 | 2019 | |
| Olympus Corporation of The Americas | $7,732.37 | 2022-2025 | Spiration Valve System |
| Isoray, INC | $6,859.99 | 2021 | |
| Gyrus Acmi, INC. | $5,999.59 | 2020-2025 | Spiration Valve System |
| Imbio INC. | $5,681.50 | 2021-2023 | Imbio Lung Density Analysis |
| Serpex Medical INC | $5,613.55 | 2024-2025 | |
| Glaxosmithkline, LLC. | $4,564.49 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $4,506.87 | 2019-2025 | Dupixent |
| Broncus Medical | $4,327.07 | 2019-2020 | |
| Auris Health, INC. | $3,459.65 | 2019 | |
| Spiration, INC. | $1,614.95 | 2019 | |
| Body Vision Medical INC. | $1,318.51 | 2023-2024 | Lungvision |
| Veran Medical Technologies, INC. | $1,111.73 | 2019-2023 | |
| Astrazeneca Uk Limited | $1,074.00 | 2022 | |
| Mauna Kea Technologies, INC. | $931.19 | 2022 | |
| Galvanize Therapeutics, INC | $673.20 | 2022-2025 | Aliya System |
| Ambu INC. | $392.81 | 2021-2022 | |
| Medtronic, INC. | $245.81 | 2021-2022 | |
| Verona Pharma, INC. | $169.06 | 2025 | Ohtuvayre |
| Pinnacle Biologics, INC | $142.60 | 2021-2023 | Photofrin |
| 4dmedical USA INC | $114.66 | 2024 | Ct Lvas |
| Janssen Research & Development, LLC | $112.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.81 | 2021 | |
| Philips North America LLC | $97.41 | 2021-2022 | |
| United Therapeutics Corporation | $57.63 | 2024 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $40.81 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $34.66 | 2019-2020 | |
| Pfizer INC. | $34.60 | 2019-2020 | |
| Cook Medical LLC | $33.25 | 2023 | Wayne |
| Mylan Specialty L.P. | $33.16 | 2019-2023 | Yupelri |
| Abbvie INC. | $27.49 | 2019-2023 | |
| Horizon Therapeutics Plc | $20.87 | 2019 | |
| Electromed, INC. | $19.99 | 2025 | Smartvest |
| Regeneron Pharmaceuticals, INC. | $17.74 | 2024 | Dupixent |
| Vifor Pharma, INC. | $17.36 | 2025 | Veltassa |
| Genentech, INC. | $13.25 | 2021-2022 | |
| Csl Behring | $12.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.45 | 2019 | |
| Intuitive Surgical, INC. | $8.85 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$262,987.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Hogarth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.